Role of heparan sulfate in ocular diseases
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Heparan sulfate (HS), a ubiquitous and structurally diverse cell surface polysaccharide and extracellular matrix component, is a factor common to several major eye pathologies. Its multitude of functions and variable distribution among the different ocular tissues makes it an important contributor to a variety of disease states. Although HS facilitates the pathogenesis of many disorders, its role in each varies. Unique functions of HS have been particularly noted in viral and bacterial keratitis and age-related macular degeneration. Combined, these pathologies comprise a large portion of conditions leading to visual impairment worldwide. Given this prevalence of diseases facilitated by HS, it is prudent to take an in-depth look at this compound in the context of these pathologic states. While the initial part of the review will discuss the pathogenic aspects of HS, it is also important to consider the wider implications of such roles for HS. The remainder of the article will specifically address one such implication, the possibility for future use of novel HS-based therapeutics to combat these eye pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 2×
“…polymorphism, Y402H, which is a variation has been associated with increased risk for AMD development (Despriet et al. 2006; Edwards et al. 2005; Hageman et al. 2005; Haines et al. 2005; Klein et al. 2005) and is thought to comprise the major genetically-based risk factor for AMD (Hecker et al.…”
Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
Esko, J. D., & Selleck, S. B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135458 · Cited by 1,495 · cited 1×
“The HS chain itself begins with the addition of a β-D-glucoasmine (GlcN) that is N-acetylated, Nacetylated GlcN (GlcNAc), to this core (Esko and Selleck 2002).”
BackgroundHageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265 · cited 2×
“Drusen buildup is also correlated to the amount of inflammation that occurs when there is inadequate inactivation of the complement system where the RPE and Bruch’s membrane meets (Hageman et al. 2001).”
BackgroundHeparin and heparan sulfate: Structure and function
Rabenstein, D. L. (2002) · Natural Product Reports · doi:10.1039/b100916h · Cited by 870 · cited 5×
“From this core, N-sulfate, O-sulfate, and N-acetyl groups can be substituted for the disaccharide subunits, allowing for the generation of many complex heparan sulfate sequences (Rabenstein 2002).”
BackgroundInfluentialAnderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727
Age-related macular degeneration
Coleman, H. R., Chan, C.-C., Ferris, F. L., & Chew, E. Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61759-6 · Cited by 542
Despriet, D. D. G., Klaver, C. C. W., Witteman, J. C. M., Bergen, A. A. B., Kardys, I., de Maat, M. P. M., Boekhoorn, S. S., Vingerling, J. R., Hofman, A., Oostra, B. A., et al. (2006) · JAMA · doi:10.1001/jama.296.3.301 · Cited by 348 · cited 1×
“…studies have identified a specific CFH gene polymorphism, Y402H, which is a variation has been associated with increased risk for AMD development (Despriet et al. 2006; Edwards et al. 2005; Hageman et al. 2005; Haines et al. 2005; Klein et al. 2005) and is thought to comprise the major…”
BackgroundClark, S. J., Higman, V. A., Mulloy, B., Perkins, S. J., Lea, S. M., Sim, R. B., & Day, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605083200 · Cited by 185 · cited 2×
“Age may also play a factor in determining when this polymorphism manifests itself phenotypically, as GAG structures are known to be prone to age-dependent changes (Clark et al. 2006; Feyzi et al. 1998).”
BackgroundA heparin mimetic isolated from a marine shrimp suppresses neovascularization
DREYFUSS, J. L., REGATIERI, C. V., LIMA, M. A., PAREDES‐GAMERO, E. J., BRITO, A. S., CHAVANTE, S. F., BELFORT JR, R., FARAH, M. E., & NADER, H. B. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03916.x · Cited by 38
Cited by
Clark, S. J., Schmidt, C. Q., White, A. M., Hakobyan, S., Morgan, B. P., & Bishop, P. N. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401613 · Cited by 122
Keenan, T. D. L., Pickford, C. E., Holley, R. J., Clark, S. J., Lin, W., Dowsey, A. W., Merry, C. L., Day, A. J., & Bishop, P. N. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.14-14126 · Cited by 65
Petsevа, Y., Mladenova, K., Ganeva, M., Radeva, V., Videv, P., Doumanov, J., & Petrova, S. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110351 · Cited by 2
Metadata
- Authors
- Park, P. J., & Shukla, D.
- Venue
- Experimental Eye Research
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 110
- Pages
- 1-9
- ISSN
- 0014-4835 (ISSN-L)
- OpenAlex
- W2013522806
- Cited by
- 34
- References
- 10
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.